Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on October 17, 2025, that its Human...
Huadong Medicine Secures NMPA Approval for Relmapirazin Injection, Complementing MediBeacon TGFR Device
Huadong Medicine (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has granted marketing...
Kexing Biopharm & Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide
Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co.,...
Sinclair’s MaiLi Precise Receives NMPA Acceptance Notice for Class III Device
Sinclair (Hangzhou) Medical Technology Co., Ltd., a wholly‑owned subsidiary of Huadong Medicine (SHE: 000963), announced...
I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101
I‑MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic...
CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC
CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal...
Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia
Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining...
Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has signed a Memorandum of...
Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110
Hansoh Pharmaceutical Group (HKG: 3692) today announced a licensing agreement with Roche (SWX: ROG, OTCMKTS:...
Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food...
AstraZeneca China Integrates Symbicort and Breztri Sales Teams in New Organizational Shake‑Up
AstraZeneca (AZ; NASDAQ: AZN) announced a strategic re‑alignment of its respiratory inhalation portfolio in China, consolidating...
Leads Biolabs, Dianthus Therapeutics Announce Global Partnership for LBL‑047 Bispecific Fusion Protein
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus Therapeutics...
NeuroGen Pharma Secures Exclusive Rights to Brexpiprazole Orally Disintegrating Film from Bocimed
China‑based NeuroGen Pharma and Bocimed announced today that they have entered into an exclusive product‑transfer...
Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy
Chia Tai Tianqing, a wholly‑owned subsidiary of Sino Biopharmaceutical (HKG: 1177), announced today that the...
Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC
Lepu Biopharma Co., Ltd. (HKG: 2157) announced today that it has successfully enrolled the first...
Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital
Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi...
HELP Therapeutics Secures NMPA Approval for HiCM388, China’s First Cell‑Based Therapy for STEMI
HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...
Abbott Reports Q3 2025 Revenue of $11.369 B, Up 6.9% YoY – Strong Growth Across Nutrition & Devices Segments
Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September 30, 2025. For...
Haihe Biopharma Grants Taiho Pharmaceutical Exclusive License for Risovalisib in Japan
China‑based Haihe Biopharma Co., Ltd. (the “Licensor”) announced today that it has entered into an...